ANTERN (LAser Nerve ThERapy for chemotherapy Neurotoxicity):Randomized controlled phase 2 trial evaluating laser photobiomodulation for the treatment of chemotherapy-induced peripheral neuropathy (CIPN)

Concord Cancer Centre0 个研究点目标入组 45 人开始时间: 2019年11月28日最近更新: 2020年8月24日

适应症

试验速览

暂无简介。

•1.Males or females with chemotherapy-induced peripheral neuropathy symptoms;
•2.At least 3 months following last exposure to neurotoxic chemotherapy, including taxane and platinum classes
•3.Age >18 years
•4.Agree not to undertake any complementary therapy for peripheral neuropathy for the duration of participation on the study
•5.Speak and read sufficient English to answer the questionnaires
•6.Available for treatment and follow up visits
•7.Signed, written informed consent

•1.Inability to lie supine for a 30-minute period
•2.Open wound or ulcer over the treatment area
•3.Clinical diagnosis of peripheral neuropathy from another cause, eg. diabetic peripheral neuropathy, B12 or folate deficiency, alcoholic neuropathy, or demyelination. Note diabetes is not a specific exclusion.
•4.Uncontrolled psychiatric illness, dementia or cognitive dysfunction that in the opinion of the principal investigator may interfere with the ability to complete neurotoxicity assessments
•5.Life expectancy of <3 months

发起方

Concord Cancer Centre